TABLE II.
Full Cohort % (n) |
Female odds ratio |
21–25y odds ratio |
26–30y odds ratio |
31–50y odds ratio |
UBE3A odds ratio |
UPD odds ratio |
|
---|---|---|---|---|---|---|---|
| |||||||
History of seizures | 94% (109) | 0.437 | IS (100%, 29) | 0.335 | 0.775 | IS (100%, 9) | 0.111* |
Current seizures | |||||||
Seizure free/off AEDs a | 12% (103) | 0.937 | 0.786 | 1.197 | 2.470 | 1.584 | 0.792 |
Seizure free/AED Tx a | 48% (103) | 0.844 | 0.525 | 0.238* | 0.202* | 0.945 | 1.970 |
Active seizures b | 41% (103) | 1.154 | 2.345 | 4.102* | 6.701* | 1.853 | 0.494 |
Current AED ≥2 | 45% (103) | 0.676 | 2.241 | 1.445 | 1.556 | 0.625 | 0.750 |
≥ 2 semiologies c | 12% (103) | 0.497 | 1.418 | 2.966 | 1.832 | IS (0%, 9) | 0.886 |
Frequency | |||||||
Monthly d | 29% (103) | 1.021 | 3.051 | 4.558* | 7.802* | 1.214 | 0.810 |
Daily | 16% (103) | 2.266 | 2.11 | 10.328* | 6.883* | 0.567 | IS (0%, 8) |
Seizure severity | |||||||
Modified E-chess score δ | 4.65 (SD: 2.754, n=103) | 0.055 | 0.807 | 1.706** | 1.688** | -0.139 | -0.569 |
Score > 6 | 26% (103) | 0.817 | 1.464 | 3.032 | 2.28 | 0.857 | 1.000 |
Current medications | |||||||
Valproate | 39% (103) | 0.673 | 1.614 | 2.234 | 1.493 | 0.424 | 0.890 |
Clonazepam | 17% (103) | 1.033 | 1.232 | 0.431 | 0.277 | IS (0%, 9) | 0.500 |
Lamotrigine | 17% (103) | 1.809 | 2.080 | 0.622 | 0.855 | 0.567 | 0.648 |
Levetiracetam | 13% (103) | 0.588 | 3.948 | 0.955 | 9.329* | 0.775 | IS (0%, 8) |
Ethosuximide | 9% (103) | 0.49 | 0.198 | 0.279 | 0.383 | 1.675 | 1.914 |
Topiramate | 9% (103) | 0.264 | 0.258 | 0.653 | 0.477 | 3.943 | 1.533 |
Lifetime seizure severity | |||||||
AEDs >2 lifetime | 63% (103) | 1.782 | 2.020 | 1.188 | 1.577 | 0.283 | 0.942 |
AEDs >3 lifetime | 45% (103) | 1.107 | 2.455 | 2.008 | 1.754 | 0.140 | 0.671 |
Seizure onset <3y | 68% (103) | 0.847 | 1.555 | 2.076 | 2.777 | 0.206* | 1.235 |
Most severe age δ | 7.53 (SD: 7.035, n=100) | 1.192 | 1.772 | −0.111 | 4.041 | −2.536 | 1.339 |
0–5 y | 52% (100) | 0.472 | 0.863 | 0.667 | 1.827 | 2.000 | 1.000 |
6–10 y | 25% (100) | 0.875 | 0.568 | 1.071 | 0.154 | 0.964 | 0.482 |
11–15 y | 12% (100) | 4.519* | 0.922 | 2.956 | 0.602 | IS (0%, 9) | 0.766 |
16–20 y | 6% (100) | 6.19 | 2.827 | IS (0%, 18) | IS (0%, 15) | 2.062 | 2.357 |
21–25 y | 5% (62) | 2.370 | -- | -- | -- | IS (0%, 5) | 7.167 |
26–30 y | 0% (33) | -- | -- | -- | -- | -- | -- |
>31 y | 20% (15) | 0.500 | -- | -- | -- | IS (0%, 2) | IS (0%, 1) |
Age sub-groups compared with the 16–20y cohort. Genotype sub-groups compared with the Del cohort.
cohort of individuals with history of seizures who have not had an event in 1 year or more.
includes 3 individuals who were not being treated with an AED.
reported to have 2 or more types of seizure, i.e. events that look different to caregiver.
events occurring at least monthly. δ. regression coefficient listed for each covariate.
statistically significant odds ratio (α = 0.05).
statistically significant regression coefficient (α=0.05). IS: infinite solution (%, n), AED: anti-epileptic drugs, Tx: treatment, y: years.